Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-07-31 Share Issue/Capital Cha…
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
PROSPECTUS - up to an aggregate of11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares
Share Issue/Capital Change Classification · 95% confidence The document is explicitly titled "PROSPECTUS" and details the resale of American Depositary Shares (ADSs) by selling shareholders, referencing specific warrant types (Series A-1 Warrants, Series A-2 Warrants, Placement Agent Warrants) and a recent transaction (July 2024 Transaction). It discusses listing on Nasdaq and TASE, and incorporates by reference the company's most recent Annual Report on Form 20-F. A prospectus is a formal legal document required for the public offering or resale of securities. Among the provided codes, 'CAP' (Capital/Financing Update) is the closest fit for a document detailing the structure and resale of securities, although 'PSI' (Proxy Solicitation & Information Statement) or 'RPA' (Report Publication Announcement) are less fitting as this is the primary offering document itself, not a proxy or an announcement of another report. Given the context of securities offering/resale documentation, this falls under the broad category of capital market activities. However, none of the codes perfectly match a standard SEC registration statement like a Prospectus (S-1, F-1, etc.). Since the document is about the offering/resale of securities and capital structure changes related to warrants, 'CAP' (Capital/Financing Update) is the most appropriate category among the choices, as it relates directly to the issuance and structure of capital instruments being sold to the public/resold. If a code for Registration Statement (like S-1/F-1) existed, that would be preferred. Given the options, 'CAP' is selected due to the focus on warrants and share resale.
2024-07-31 English
PROSPECTUS - up to an aggregate of11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares
Capital/Financing Update Classification · 95% confidence The document is a filing by PURPLE BIOTECH LTD, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key indicator is the header: "PURPLE BIOTECH LTD PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3) Registration No. 333-280947". A Prospectus Supplement filed under Rule 424(b)(3) relates to securities offerings and capital structure changes. This aligns best with the 'Capital/Financing Update' category (CAP), which covers fundraising and capital structure changes. Although it is a specific SEC filing type, among the provided options, CAP is the most appropriate fit for a prospectus supplement related to an offering, rather than a general regulatory filing (RNS) or a standard periodic report (10-K, IR). The document explicitly mentions a 'PROSPECTUS SUPPLEMENT'.
2024-07-31 English
Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Regulatory Filings Classification · 96% confidence The document is explicitly titled "FORM 6-K" and is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934." This form is used for current reports filed by foreign private issuers. The content announces an extension received from Nasdaq regarding the minimum bid price rule and includes a press release as Exhibit 99.1. A Form 6-K is a periodic/current report, but it does not align perfectly with the provided specific codes (10-K for annual, IR for comprehensive interim). Since it is a current report containing material information that doesn't fit the other specific categories (like ER for initial earnings release, or DIV for dividend notice), it falls best under the general regulatory filing category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous SEC filings not covered by the primary definitions. Although it is a formal SEC filing, RNS is the most appropriate fit among the given options for a Form 6-K.
2024-07-25 English
Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Report Publication Announcement Classification · 95% confidence The document is a short notification from Purple Biotech Ltd regarding a Form 6-K filing. It explicitly states 'Attached hereto is a report on 6K: Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, and it fits the definition of a Report Publication Announcement (RPA).
2024-07-25 English
FORM F-1-ADS resale by the selling shareholders
Capital/Financing Update Classification · 95% confidence The document explicitly states it is a "FORM F-1" and a "REGISTRATION STATEMENT" under the Securities Act of 1933. It is a prospectus related to the resale of American Depositary Shares by selling shareholders. A Form F-1 is the standard registration statement required for foreign private issuers registering securities for public offering in the U.S. This filing type is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, a Registration Statement (like F-1, S-1, etc.) is a primary regulatory filing used to register securities for sale. Since the definitions lack a specific code for general SEC Registration Statements, and given that this document is a comprehensive filing related to securities registration and offering, it is best categorized as a general Regulatory Filing (RNS) or potentially related to Capital/Financing (CAP) due to the nature of the offering. Given the context of SEC filings, RNS (Regulatory Filings) is the most appropriate fallback for a document type not specifically covered, as it is a core regulatory document. Reviewing the definitions, none perfectly match 'Registration Statement/Prospectus' (like S-1 or F-1). 'CAP' (Capital/Financing Update) is plausible as it relates to an offering, but 'RNS' (Regulatory Filings - General regulatory announcements and fallback category) is the designated catch-all for filings that don't fit elsewhere. Since this is a foundational SEC registration document, RNS is the most suitable classification among the choices provided.
2024-07-22 English
FORM F-1-ADS resale by the selling shareholders
Report Publication Announcement Classification · 98% confidence The document is a short regulatory filing (1908 characters) published via MAGNA, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content is an 'Immediate report on other matter' which explicitly states: '*FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PURPLE BIOTECH LTD*' and lists an 'Attached file *ea020978901-f1_purplebioEDGAR4_bannerless_isa.pdf*'. Since this is a brief announcement stating that a specific, major regulatory document (a Form F-1 Registration Statement) is attached or published, it fits the definition of a Report Publication Announcement (RPA) rather than the full registration statement itself. It is not a standard 10-K, IR, or ER.
2024-07-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.